Plain-English translation of NCT07237568 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called to see if it can help reduce symptoms of ankylosing spondylitis, a condition that causes inflammation and stiffness in the spine. Half of the participants will receive the medication for the full 52 weeks, while the other half will first receive a placebo (inactive pill) for 16 weeks, then switch to the medication for 36 weeks. The study will measure how well the medication works and whether it is safe.
Ankylosing spondylitis can be very painful and limit movement, and many patients do not respond well enough to current treatments like NSAIDs. This trial is testing whether this new medication could be a better option for people whose pain and inflammation are not well controlled by existing drugs.
You likely qualify if…
You likely don't qualify if…
You would take a pill twice daily for 52 weeks total. For the first 16 weeks, you would either receive the new medication or a placebo (and you would not know which). If you receive the placebo, you would switch to the actual medication at week 16. Throughout the study, you would have clinic visits to check how you are doing, measure your pain and stiffness, and monitor for any side effects.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China